DOCSLIB.ORG

A Systematic Review of Proton Pump Inhibitors for the Treatment of Adult Patients with Symptomatic Gastroesophageal Reflux Disease Or Peptic Ulcer Disease

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Systematic Review of Proton Pump Inhibitors for the Treatment of Adult Patients with Symptomatic Gastroesophageal Reflux Disease Or Peptic Ulcer Disease Title A systematic review of proton pump inhibitors for the treatment of adult patients with symptomatic gastroesophageal reflux disease or peptic ulcer disease. Review Question(s) Requested Requested by PSD 1. What is the comparative effectiveness of different proton pump inhibitors in patients with symptoms of gastroesophageal reflux disease? 2. What is the comparative effectiveness of different proton pump inhibitors in treating peptic (duodenal and gastric) ulcer? 3. What are the comparative safety and adverse events of different proton pump inhibitors in patients being treated for symptoms of gastroesophageal reflux disease and peptic ulcer? 4. Are there subgroups of patients based on demographics, other medications, or comorbidities (including nasogastric tubes and inability to swallow solid oral medication) for which a particular proton pump inhibitor or preparation is more effective or associated with fewer adverse effects? Drug The following five proton pump inhibitors (PPI) drugs will be reviewed 1. Esomeprazole (Nexium® and its generic equivalent) 2. Lansoprazole (Prevacid® and its generic equivalent) 3. Omeprazole* (Losec® and its generic equivalent) 4. Pantoprazole* sodium and magnesium (Pantoloc®, Panto IV and their generic equivalent and Tecta® 5. Rabeprazole* (Pariet® and its generic equivalent) Note: *Omeprazole, Pantoprazole and Rabeprazole have been identified as reference drugs by PSD. Esomeprazole and Lansoprazole will be compared to these three reference drugs. TABLE OF CONTENTS TABLE OF CONTENTS ..........................................................................................................................2 List of Tables ......................................................................................................................................4 List of figures .....................................................................................................................................6 ABBREVIATIONS .................................................................................................................................9 1 EXECUTIVE SUMMARY ............................................................................................................. 11 1.1 Background ..................................................................................................................... 11 1.2 Research Questions (according to Cochrane ‘PICOS’ format) ............................................. 11 1.3 Method ........................................................................................................................... 12 1.4 Results ............................................................................................................................. 12 1.5 Strengths of review .......................................................................................................... 19 1.6 Limitations of review ....................................................................................................... 19 1.7 Overall Summary of findings ............................................................................................ 20 1.8 Conclusions ..................................................................................................................... 23 2 INTRODUCTION........................................................................................................................ 24 2.1 Disease Prevalence and Incidence .................................................................................... 24 2.2 Standard of Therapy ........................................................................................................ 25 2.3 Drug ................................................................................................................................ 26 2.3.1 Drug characteristics: ............................................................................................................................ 26 2.4 Goals of Therapy .............................................................................................................. 27 2.5 Guidelines ....................................................................................................................... 27 3 OBJECTIVES AND METHODS: .................................................................................................... 31 3.1 Objectives requested (PICOS format) ................................................................................ 31 3.2 Methods: ......................................................................................................................... 32 3.2.1 Eligibility Criteria .................................................................................................................................. 32 3.2.2 Search strategy and findings ................................................................................................................ 33 3.2.3 Study selection ..................................................................................................................................... 33 3.2.4 Data extraction and synthesis .............................................................................................................. 33 3.2.5 Quality Assessment:............................................................................................................................. 34 3.2.6 Data synthesis ...................................................................................................................................... 35 3.2.7 Assessment of Publication bias ............................................................................................................ 35 3.2.8 Additional analyses .............................................................................................................................. 35 3.2.1 Sensitivity analyses .............................................................................................................................. 35 RESULTS .......................................................................................................................................... 36 3.3 Findings from the Literature ............................................................................................. 36 June 6th 2014 3.4 Trials meeting inclusion criteria are listed according to specific comparisons ..................... 41 3.4.1 Description of studies .......................................................................................................................... 48 3.4.2 Population ............................................................................................................................................ 50 3.4.3 Interventions ........................................................................................................................................ 52 3.4.4 Outcomes (primary and other outcomes) ........................................................................................... 54 3.4.5 Statistical Analysis ................................................................................................................................ 55 3.5 Patient Disposition ........................................................................................................... 55 3.6 Exposure to treatment ..................................................................................................... 57 3.6.1 Investigational products ...................................................................................................................... 57 3.6.2 Concomitant Medications.................................................................................................................... 57 3.7 Critical Appraisal .............................................................................................................. 58 3.7.1 Internal Validity ................................................................................................................................... 58 3.7.2 Other Sources of Bias ........................................................................................................................... 68 3.7.3 External validity ................................................................................................................................... 70 3.8 Results of Individual studies ............................................................................................. 71 3.8.1 Efficacy results from RCTs .................................................................................................................... 71 3.8.2 Subgroup analysis from included RCTs ................................................................................................ 88 3.8.3 Harms from RCTs ............................................................................................................................... 102 3.9 Comparative and overall safety of PPI drug class ............................................................ 121 3.10 Synthesis of Results ....................................................................................................... 131 4 DISCUSSION ........................................................................................................................... 141 4.1 Summary of Available Evidence ...................................................................................... 141 4.2 Interpretation of Results ...............................................................................................
Load more

Recommended publications
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Comparative Efficacy of Various Anti-Ulcer Medications After Gastric Endoscopic Submucosal Dissection: a Systematic Review and Network Meta-Analysis
    Surgical Endoscopy (2019) 33:1271–1283 and Other Interventional Techniques https://doi.org/10.1007/s00464-018-6409-4 Comparative efficacy of various anti-ulcer medications after gastric endoscopic submucosal dissection: a systematic review and network meta-analysis Eun Hye Kim1 · Se Woo Park2 · Eunwoo Nam3 · Jae Gon Lee4 · Chan Hyuk Park4 Received: 4 May 2018 / Accepted: 24 August 2018 / Published online: 30 August 2018 © Springer Science+Business Media, LLC, part of Springer Nature 2018 Abstract Background The comparative efficacy of various anti-ulcer medications after gastric endoscopic submucosal dissection (ESD) has not been fully evaluated. Recently, vonoprazan, a novel potassium-competitive acid blocker, has also been used in ulcer treatment after ESD. Methods We searched for all relevant randomized controlled trials examining the efficacy of anti-ulcer medications after gastric ESD, published through October 2017. Healing of iatrogenic ulcers was investigated at 4–8 weeks after ESD. A network meta-analysis was performed to calculate the network estimates. Results Twenty-one studies with 2005 patients were included. Concerning the comparative efficacy for ulcer healing at 4 weeks after ESD, no network inconsistency was identified (Cochran’s Q-test, df = 10, P = 0.13; I2 = 34%). A combination therapy of proton-pump inhibitor (PPI) and muco-protective agent was superior to PPI alone [risk ratio (RR) (95% confi- dence interval, CI) 1.69 (1.20–2.39)]. The combination therapy of PPI and muco-protective agents tended to be superior to vonoprazan [RR (95% CI) 1.98 (0.99–3.94)]. There was no difference of ulcer healing effect between PPI and vonoprazan [RR (95% CI) PPI vs.
    [Show full text]
  • Bismuth Salts for Gastrointestinal Issues: a Review of the Clinical Effectiveness and Guidelines DATE
    TITLE: Bismuth Salts for Gastrointestinal Issues: A Review of the Clinical Effectiveness and Guidelines DATE: 24 November 2015 CONTEXT AND POLICY ISSUES Oral bismuth formulations have been used effectively for prophylaxis and treatment of both diarrhea and for treatment of Helicobacter pylori (H. pylori) infection.1,2 Bismuth formulations available without a prescription have been commonly used to treat episodic diarrhea for over a century. Bismuth has also been used to treat ulcers prior to the appreciation of its antimicrobial activity against the then unknown causative micro-organism, H. pylori.1 Episodes of diarrhea are especially common in travelers to resource-poor countries. It is estimated that 30% to 70% of international travelers will develop diarrhea during travels or upon return. Typically diarrhea is self-diagnosed and the causal infectious agent remains unknown. While the condition is frequently self-limiting, treatment can reduce the duration, severity, and inconvenience of diarrhea while travelling. Commonly used treatments include antibiotics, antimotility agents, oral rehydration solutions, and bismuth subsalicylate.2 H. pylori infection is a substantial public health concern as it plays a causative role in the pathogenesis of many gastrointestinal conditions such as gastritis, peptic ulcers, and gastric cancer.3 Current treatment regimens designed to eradicate infection utilize more than one antibiotic simultaneously in a standard triple therapy (STT) consisting of a proton-pump inhibitor (PPI), and two antibiotics.
    [Show full text]
  • New and Future Drug Development for Gastroesophageal Reflux Disease
    J Neurogastroenterol Motil, Vol. 20 No. 1 January, 2014 pISSN: 2093-0879 eISSN: 2093-0887 http://dx.doi.org/10.5056/jnm.2014.20.1.6 JNM Journal of Neurogastroenterology and Motility Review New and Future Drug Development for Gastroesophageal Reflux Disease Carla Maradey-Romero and Ronnie Fass* The Esophageal and Swallowing Center, Division of Gastroenterology and Hepatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio, USA Medical therapy remains the most popular treatment for gastroesophageal reflux disease (GERD). Whilst interest in drug devel- opment for GERD has declined over the last few years primarily due to the conversion of most proton pump inhibitor (PPI)’s to generic and over the counter compounds, there are still numerous areas of unmet needs in GERD. Drug development has been focused on potent histamine type 2 receptor antagonist’s, extended release PPI’s, PPI combination, potassium-competitive acid blockers, transient lower esophageal sphincter relaxation reducers, prokinetics, mucosal protectants and esophageal pain modulators. It is likely that the aforementioned compounds will be niched for specific areas of unmet need in GERD, rather than compete with the presently available anti-reflux therapies. (J Neurogastroenterol Motil 2014;20:6-16) Key Words Erosive esophagitis; Gastroesophageal reflux; Heartburn; Proton pump inhibitors Most patients with GERD fall into 1 of 3 categories: non- erosive reflux disease (NERD), erosive esophagitis (EE), and Introduction Barrett’s esophagus (BE). The 2 main phenotypes of GERD, Gastroesophageal reflux disease (GERD) is a common con- NERD and EE, appear to have different pathophysiological and dition that develops when reflux of stomach contents cause trou- clinical characteristics.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • Effect of Ilaprazole on the Healing of Endoscopic Submucosal Dissection-Induced Gastric Ulcer: Randomized-Controlled, Multicenter Study
    Surgical Endoscopy (2019) 33:1376–1385 and Other Interventional Techniques https://doi.org/10.1007/s00464-018-6412-9 Effect of ilaprazole on the healing of endoscopic submucosal dissection-induced gastric ulcer: randomized-controlled, multicenter study Chang Seok Bang1,2 · Woon Geon Shin1,3 · Seung In Seo1 · Min Ho Choi1 · Hyun Joo Jang1 · Se Woo Park1 · Sea Hyub Kae1 · Young Joo Yang1 · Suk Pyo Shin1 · Gwang Ho Baik1 · Hak Yang Kim1 Received: 18 May 2018 / Accepted: 24 August 2018 / Published online: 30 August 2018 © Springer Science+Business Media, LLC, part of Springer Nature 2018 Abstract Background The optimal treatment regimen or the duration of treatment for an endoscopic submucosal dissection (ESD)- induced gastric ulcer has not been established. The aim of this study was to assess the efficacy of novel proton-pump inhibitor, ilaprazole, for the treatment of ESD-induced gastric ulcer. Methods This was a prospective, open-label, randomized multicenter study. Between June 2015 and March 2018, a total of 176 patients (178 lesions) who underwent ESD for a gastric neoplasm were randomly allocated to receive the oral proton- pump inhibitor ilaprazole 20 mg or rabeprazole 20 mg daily for 8 weeks. The primary outcome was the ulcer healing rate at 4 and 8 weeks. Results A total of 155 (157 lesions) and 154 patients (156 lesions) were included in the modified intention-to-treat (mITT) and per-protocol analyses, respectively. There was no significant difference in the ulcer healing rate (ilaprazole vs. rabepra- zole, 97.4% vs. 97.0 p = 0.78 at 4 weeks, 100% vs. 100%, p = 0.95 at 8 weeks in the mITT analysis) or stage of ulcer (scar stage, 25.6% vs.
    [Show full text]
  • Cytochrome P450 Enzymes in Drug Metabolism: Regulation of Gene Expression, Enzyme Activities, and Impact of Genetic Variation
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Pharmacology & Therapeutics 138 (2013) 103–141 Contents lists available at SciVerse ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Associate editor: H. Bönisch Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation Ulrich M. Zanger ⁎, Matthias Schwab Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Auerbachstr. 112 D, 70376 Stuttgart, Germany Department of Clinical Pharmacology, The University of Tuebingen Medical Faculty, Tuebingen, Germany article info abstract Keywords: Cytochromes P450 (CYP) are a major source of variability in drug pharmacokinetics and response. Of 57 Biotransformation putatively functional human CYPs only about a dozen enzymes, belonging to the CYP1, 2, and 3 families, Cytochrome P450 monooxygenase are responsible for the biotransformation of most foreign substances including 70–80% of all drugs in clinical NADPH:cytochrome P450 reductase use. The highest expressed forms in liver are CYPs 3A4, 2C9, 2C8, 2E1, and 1A2, while 2A6, 2D6, 2B6, 2C19 and Pharmacogenetics 3A5 are less abundant and CYPs 2J2, 1A1, and 1B1 are mainly expressed extrahepatically. Expression of each Polymorphism CYP is influenced by a unique combination of mechanisms and factors including genetic polymorphisms, Xenobiotic induction by xenobiotics, regulation by cytokines, hormones and during disease states, as well as sex, age, and others. Multiallelic genetic polymorphisms, which strongly depend on ethnicity, play a major role for the function of CYPs 2D6, 2C19, 2C9, 2B6, 3A5 and 2A6, and lead to distinct pharmacogenetic phenotypes termed as poor, intermediate, extensive, and ultrarapid metabolizers.
    [Show full text]
  • Korea Innovative PHARMACEUTICAL Company Potential of Pharmaceutical Industry in Korea
    2017 Korea Innovative PHARMACEUTICAL Company Potential of Pharmaceutical Industry in Korea Aging populations and growing interest in health and welfare continue companies have developed therapies in an array of areas including oncology, antibacterial, gastritis, respiratory to drive up the demand for innovative drugs across the world. Globally, infections, duodenal ulcer, diabetic foot ulcer, erectile dysfunction, hepatitis B and hypertension. R&D spending in the pharmaceutical industry was higher than any Development of innovative drugs targeting other industry (pharmaceutical and bio ranked No. 1 with 150 billion Drug development the global market Early years of drug getting on track 2010’s dollars(2015)), indicating that the future industrial structure is shifting Development of development Local manufacturing of 2000’s finished products and new processes from IT to pharmaceutical business. drug substance 1990’s 1980’s 1960/70’s Pharmaceutical Industry in Korea Launch of innovative drugs(total of 27) ’99 ’01 ’02 ’03 ’05 ’06 ’07 ’08 ’10 ’12 ’13 ’14 ’15 2016 In Korean, the value of drugs manufactured in Korea was KRW 16.9 trillion in 2015. The annual average growth rate for the past five years was 4.7 percent. In addition, the size of the pharmaceutical market was KRW 19.2 trillion in 2015. Sunpla EGF Factive Apitoxin Revanex Levovir Pelubi Noltec Pyramax Supect Duvie Riavax Acelex Olita Tab Milican Peudovaccin Zydena Mvix Kanab Zemiglo Zabolante Size and Market Trends in Pharmaceutical Industry in Korea (Unit: KRW Trillion, %) Category
    [Show full text]
  • Pharmacological Management of Gastro-Esophageal Reflux Disease: an Update of the State-Of-The-Art
    Drug Design, Development and Therapy Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW Pharmacological Management of Gastro-Esophageal Reflux Disease: An Update of the State-of-the-Art Vincenzo Savarino 1 Abstract: Gastro-esophageal reflux disease (GERD) is a highly prevalent, chronic disorder, Elisa Marabotto1 whose knowledge remains limited and the management of these patients changes continu­ Patrizia Zentilin 1 ously. This review provides a summary of the most recent advancements in the pathogenesis Maria Giulia Demarzo1 of this disease and the new drugs introduced into the market to overcome some of the unmet Nicola de Bortoli2 needs of traditional therapies. Nowadays, the most fruitful diagnostic examinations are 24- hour impedance-pH monitoring, which allows us to separate true NERD from esophageal Edoardo Savarino 3 functional disorders and high-resolution manometry, which helps to exclude the existence of 1Department of Internal Medicine (DIMI), motility disorders sharing the same symptoms of GERD. Proton pump inhibitors (PPIs) University of Genoa, Genoa, Italy; 2Department of Translational Research remain the first-choice therapy in the treatment of GERD, but a consistent proportion of these and New Technologies in Medicine and patients continue to experience symptoms despite their intake. These cases pertain mainly to Surgery, University of Pisa, Pisa, Italy; the subpopulation with non-erosive reflux disease (NERD) and represent very challenging 3Department of Surgery, Oncology and Gastroenterology, University of Padova, clinical situations, because it is mandatory to understand the reasons for PPI failure. The Padova, Italy management of these difficult patients requires necessarily to test them and avoid the use of empiric treatments that are often unsuccessful, costly and potentially dangerous.
    [Show full text]
  • Final List- Generic Drugs SPELL CHECK.Xlsx
    SL.NO GENERIC NAME Unit 1 ABDOMINAL CORSET SEGO LARGE LARGE 2 ABDOMINAL CORSET SEGO MEDIUM MEDIUM 3 ABDOMINAL CORSET SMALL SMALL 4 ABGEL ABGEL 5 ACEBROFYLLINE+ACETYLCYSTEINE 100mg,+ 600mg TABLET 6 ACEBROPHYLLINE 100MG CAPSULE 7 ACEBROPHYLLINE 200SR CAPSULE 8 ACECLOFENAC 100 MG+PARACETAMOL 325MG TABLET 9 ACECLOFENAC 100MG TABLET 10 ACECLOFENAC 100MG,PARACETAMOL 325MG,TRAMADOL 375MG TABLET 11 ACECLOFENAC 100MG,PARACETAMOL 500MG,TIZANIDINE 2MG CAPSULE 12 ACECLOFENAC 100MG+PARACETAMOL 650MG TABLET 13 A‐ CELLULER D TAP INJECTION 14 ACELOFENAC+RABIPRAZOLE TABLET 15 ACECLOFENAC+SERRATIOPEPTIDASE+PARACETAMOL (100+15+500)MG TABLET 16 ACECLOPENAC 200MG CAPSULE 17 ACENOCOUMAROL 2mg TABLET 18 ACEPTO SYRINGE PIECES 19 ACETAMINOPHEN 250 SYRUP 20 ACETAMINOPHEN 250MG 60ML SYRUP 21 ACETAMINOPHEN & PARACETAMOL TABLET 22 ACETAZOLAMIDE 250 TABLET 23 ACETYLACETYLIN SOLUTION 5ML INJECTION 24 ACETYLCYSTEINE 600MG TABLET 25 ACETYLCYSTEINE 600MG Respules ACETYL SALICYLIC ACID 350MG, CALCIUM CARBONATE 35MG, CITRIC ACID 105MG TABLET 26 27 ACICLOVIR 200MG TABLET 28 ACICLOVIR 250MG INJECTION 29 ACICLOVIR 30ML SYRUP 30 ACICLOVIR 400MG TABLET 31 ACICLOVIR 500MG INJECTION 32 ACICLOVIR 800MG TABLET 33 ACICLOVIR EYE 5% 5GM OINTMENT 34 ACICLOVIR 5GM EYE O OINTMENT 35 ADAPALENE APGEL 36 ADAPALENE TOPICAL 01%W/W,CLINDAMYCIN TOPICAL 1%W/W GEL 37 ADENOSINE 2ML INJECTION 38 ADHESIVE TAPE 4 INCH GPLAST PIECES 39 ADRENALINE 1ML INJECTION 40 ADULT DIAPER 10 LARGE LARGE 41 ADULT DIAPER 10 MEDIUM MEDIUM 42 ADULT DIAPER 5 LARGE LARGE 43 ADULT DIAPER 5 MEDIUM MEDIUM 44 AIR MITTRESS
    [Show full text]
  • Study Protocol and Also in Accordance with the Following: ! the Ethical Principles That Have Their Origin in the Declaration of Helsinki
    Title: A Phase 3 Study to Evaluate the Efficacy and Safety of Dexlansoprazole (60 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis, and Maintenance of Healing in Subjects With Healed Erosive Esophagitis With Dexlansoprazole (30 mg QD) and Placebo NCT Number: NCT02873702 Protocol Approve Date: 20 February 2017 Certain information within this protocol has been redacted (ie, specific content is masked irreversibly from view with a black/blue bar) to protect either personally identifiable information or company confidential information. This may include, but is not limited to, redaction of the following: Named persons or organizations associated with the study. Proprietary information, such as scales or coding systems, which are considered confidential information under prior agreements with license holder. • Other information as needed to protect confidentiality of Takeda or partners, personal information, or to otherwise protect the integrity of the clinical study. TITLE PAGE PROTOCOL AMENDMENT A Phase 3 Study to Evaluate the Efficacy and Safety of Dexlansoprazole (60 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis, and Maintenance of Healing in Subjects With Healed Erosive Esophagitis With Dexlansoprazole (30 mg QD) and Placebo Sponsor: Takeda Development Center Asia, Pte. Ltd. 21 Biopolis Road, Nucleos North Tower, Level 4, Singapore 138567 Study Number: TAK-390MR_301 IND Number: Not Applicable EudraCT Number: Not Applicable Compound: TAK-390MR Dexlansoprazole Capsules Date: 20 February 2017 Amendment Number: 03 Amendment History: Date Amendment Number Amendment Type Region 05 August 2011 Initial Protocol Not applicable China 16 December 2015 01 Substantial China 09 June 2016 02 Nonsubstantial China 20 February 2017 03 Nonsubstantial China CONFIDENTIAL PROPERTY OF TAKEDA This document is a confidential communication of Takeda.
    [Show full text]